Medicines Classification




NEW ZEALAND GAZETTE, No. 172

19 DECEMBER 2013


except in preparations for external use other than for the treatment of solar keratosis

Dimethyl fumarate
Dronedarone
Econazole; except in medicines for vaginal or dermal use
Eculizumab
Elvitegravir
Eribulin mesylate
Febuxostat
Ferric carboxymaltose
Fidaxomicin
Fingolimod
Follistatin
Glycopyrronium
Guaiphenesin; for oral use in medicines containing more than 2% or 200 milligrams per dose form except when specified elsewhere in this notice; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply

Icatibant
Indacaterol
Influenza vaccine; except when administered to a person 18 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health
Ingenol mebutate
Ipilimumab
Isoconazole; except in medicines for vaginal or dermal use
Ivacaftor
Linagliptin
Lixisenatide
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
Mercurochrome; except when specified elsewhere in this notice
Micafungin
Miconazole; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Nitisinone
Nomegestrol
Nystatin; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Ofatumumab
Olodaterol
Omeprazole; except when specified elsewhere in this notice
Oseltamivir; except when specified elsewhere in this notice
Pantoprazole; except when specified elsewhere in this notice
Pasireotide
Pasireotide diaspartate
Pertuzumab
Pitavastatin
Plerixafor


Prucalopride
Pseudoephedrine
Ranitidine; except when specified elsewhere in this notice; except in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply
Remestemcel-L
Retapamulin
Retigabine
Ridaforolimus
Rifaximin
Rilpivirine
Rupatadine
Sapropterin
Tafluprost
Taliglucerase alfa
Telaprevir
Terbinafine; except in medicines for dermal use
Teriflunomide
Ticagrelor
Tioconazole; except in medicines for vaginal or dermal use
Tolvaptan
Trastuzumab emtansine
Trimethoprim; except in medicines for oral use containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand College of Pharmacists’ training in the treatment of urinary tract infections
Tuberculin
Velaglucerase alfa
Vemurafenib
Vilanterol
Vismodegib
Vorinostat

Schedule 2

Restricted Medicines

Adrenaline; in medicines containing 1% or less except in medicines for injection containing 0.02% or less

Brompheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Ciclopirox; for external use in medicines containing more than 2%; in preparations for application to the nails containing more than 8%

Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia and hyperacidity or to be used on the recommendation of a registered medical practitioner that are sold in the manufacturer’s original pack containing not more than 14 days’ supply

Cyclizine; for oral use other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2013, No 172





✨ LLM interpretation of page content

🏥 Classification of Medicines (continued from previous page)

🏥 Health & Social Welfare
Medicines Act 1981, Prescription medicines, Restricted medicines, Pharmacy-only medicines, Classification